



■ TEL. : 022 - 3001 5868
■ FAX : 022 - 2405 7708
■ E-Mail : info@naxparlab.com
■ Visit us at: www.naxparlab.com
■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG NO. B, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022, INDIA

Date: 14.08.2018

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001

Sub: Submission of Un-Audited Standalone Financial Results for quarter ended 30th June, 2018
in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Ref: Parnax Lab Limited, Script Code- 506128

Dear Sir,

Kindly find enclosed herewith the following:

1. A Copy of Standalone & Consolidated Un-Audited Financial results with Limited Review Report of the Company for the First quarter ended 30th June, 2018;

Kindly take on record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For PARNAX LAB LIMITED

Bhoomi



Bhoomi Thakkar
Company Secretary & Compliance Officer

Encl: As above

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN - L36912MH1982PLC027925

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2018

(Rs. In Lakhs)

S. No.	Particulars	Unaudited	Unaudited	Unaudited	Audited
		Current Quarter Ended 30.06.18	Previous Quarter ended 31.03.2018	Corresponding Quarter Ended 30.06.2017	Year Ended 31.03.2018
I	Revenue from Operations	172.62	157.30	111.05	580.31
II	Other Income	5.16	26.09	1.27	34.83
III	Total Revenue (I+II)	177.78	183.39	112.32	615.14
IV	Expenses				
	a) Cost of Material Consumed	59.72	62.98	11.17	207.00
	b) Purchase of Stock in trade	29.12	22.62	26.47	64.89
	c) Changes in inventories of finished goods, Work in progress and stock in trade	-	11.27	-	-
	d) Employee benefits expenses	9.94	12.56	51.41	88.94
	e) Finance Cost	28.14	36.25	36.67	129.73
	f) Depreciation and amortisation expenses	1.25	8.12	11.91	44.11
	g) Other expenses	61.12	69.53	47.99	204.73
	h) Impairment of assets classified as held for disposal	-	123.41	-	123.40
	Total Expenses (IV)	189.29	346.74	185.62	862.80
V	Profit/(loss) before exceptional items and tax (III-IV)	(11.51)	(163.35)	(73.30)	(247.66)
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	(11.51)	(163.35)	(73.30)	(247.66)
VIII	Tax expense				
	a) Current Tax	-	-	-	-
	b) Deferred Tax	-	-	-	(7.66)
	c) Short (Excess) Prov for Tax for Earlier Years	-	-	-	0.02
IX	Profit/ (Loss) for the period (VII-VIII)	(11.51)	(163.35)	(73.30)	(240.02)
X	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	-	0.29	-	0.29
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XI	Total Other Comprehensive Income for the period	-	0.29	-	0.29



XII	Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)	(11.51)	(163.06)	(73.30)	(239.73)
XIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49
XIV	Earning per equity share (Not Annualised)				
	(1) Basic	(0.14)	(1.92)	(0.86)	(2.82)
	(2) Diluted	(0.14)	(1.92)	(0.86)	(2.82)

Notes-

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 14, 2018
- 2 The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter ended June 30, 2018
- 3 EPS for quarter ended is on non annualised basis.
- 4 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- 5 Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

Place : Mumbai
Date : 14-08-2018



By Order of the Board
For Parnax Lab Limited

A handwritten signature in blue ink, appearing to read "Prakash M Shah".

Prakash M Shah
Whole Time Director & CEO
DIN NO: 00440980

To

The Board of Directors,

Parnax Lab Limited,

114, Building No. 8,

Jogani Industrial Complex,

Chunabhatti, Mumbai – 400 022

1. We have reviewed the unaudited standalone financial results of **Parnax Lab Limited** ("the company") for the quarter and three months ended June 30, 2018 which are included in the accompanying "Statement of Unaudited Standalone Financial Result for the quarter and three months ended June 30, 2018" together with the relevant notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants

(FRN: 120241W)

Vinod Ladha
(Vinod Ladha)

Partner

M. No. : 104151

Place : Mumbai

Dated : 14th August, 2018



PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 3001 5656, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2018

S. No.	Particulars	(Rs. in Lakhs)			
		Unaudited Current Quarter Ended 30.06.18	Unaudited Previous Quarter ended 31.03.2018	Unaudited Correspondi ng Quarter Ended 30.06.2017	Audited Year Ended 31.03.2018
I	Revenue from Operations	2,306.40	2,165.89	2,269.20	10,549.86
II	Other Income	6.35	98.21	4.37	134.28
III	Total Revenue (I+II)	2,312.75	2,264.10	2,273.57	10,684.14
IV	Expenses				
	a) Cost of Material Consumed	1,156.89	929.67	1,378.96	5,443.93
	b) Purchase of Stock in trade	42.14	27.02	15.11	70.09
	c) Changes in inventories of finished goods, Work in progress and stock in trade	(69.98)	95.37	(141.47)	(24.34)
	d) Employee benefits expenses	297.94	319.76	272.44	1,167.84
	e) Finance Cost	91.81	104.23	110.23	434.50
	f) Depreciation and amortisation expenses	87.31	96.45	90.78	374.02
	g) Other expenses	634.58	637.88	532.17	2,792.49
	h) Impairment of assets classified as held for disposal	-	123.41	-	123.40
	Total Expenses (IV)	2,240.69	2,333.79	2,268.22	10,381.93
V	Profit/(loss) before exceptional items and tax (III-IV)	72.06	(69.69)	15.35	302.21
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	72.06	(69.69)	15.35	302.21
VIII	Tax expense				
	a) Current Tax				150.00
	b) Deferred Tax				48.08
	c) Short (Excess) Prov for Tax for Earlier Years				(1.47)
IX	Profit/ (Loss) After Tax for the period (VII-VIII)	72.06	(69.69)	15.35	105.60
X	Minority Interest Profit (Loss)	0.17	0.19	0.18	0.69
XI	Profit/ (Loss) After Share of Profit (Loss) of minority interest	71.89	(69.88)	15.17	104.91
XII	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	2.70
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XIII	Total Other Comprehensive Income for the period	-	-	-	2.70



M. S. C.

XIV	Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)	71.89	(69.88)	15.17	104.91
XV	Total profit/(loss) for the year attributable to:				
	- Owners of the Company	71.89	(69.88)	15.17	107.61
	- Non-controlling interests	0.17	0.19	0.18	0.69
XVI	Other Comprehensive income attributable to :				
	- Owners of the Company	-	-	-	2.69
	- Non-controlling interests	-	-	-	0.01
XVII	Total Comprehensive income attributable to:				
	- Owners of the Company	71.89	(69.88)	15.17	110.30
	- Non-controlling interests	0.17	0.19	0.18	0.70
XVIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49
XIX	Earning per equity share (Not Annualised)				
	(1) Basic	0.85	(0.82)	0.18	1.24
	(2) Diluted	0.85	(0.82)	0.18	1.24

Notes-

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 14, 2018
- 2 The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter ended June 30, 2018
- 3 EPS for quarter ended is on non annualised basis.
- 4 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- 5 Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

Place : Mumbai
Date : 14-08-2018



By Order of the Board
For Parnax Lab Limited

Prakash M Shah
Prakash M Shah
Whole Time Director & CEO
DIN NO: 00440980

To

**The Board of Directors,
Parnax Lab Limited,**

114, Building No. 8, Jogani Industrial Complex,
Chunabhatti, Mumbai - 400 022

1. We have reviewed the unaudited Consolidated financial results of **Parnax Lab Limited** ("the company") and **Naxpar Pharma Private Limited** ("the Subsidiary") for the quarter and three months ended June 30, 2018 which are included in the accompanying "Statement of Unaudited Consolidated Financial Result for the quarter and three months ended June 30, 2018" together with the relevant notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants

(FRN: 120241W)

Vinod Ladha
(Vinod Ladha)

Partner

M. No. : 104151

Place : Mumbai

Dated : 14th August, 2018

